Vascepa Copay Assistance Basics
Vascepa (icosapent ethyl), used to lower cardiovascular risk in high-triglyceride patients, offers a copay savings card through its manufacturer, Amarin. Eligible commercially insured patients pay as little as $0 for up to 13 fills (90-day supply each), covering deductibles, copays, and coinsurance up to $15,000 annually. No assistance after the cap.[1][2]
How Vascepa Handles Deductibles
The program explicitly applies to deductibles—patients start at $0 out-of-pocket once enrolled, even if their plan deductible isn't met. This covers brand-name Vascepa only; generic versions, if available, aren't included. Enrollment is online or by phone; income isn't a factor for commercial insurance.[2]
Comparison to Statin Copay Programs (e.g., Crestor, Lipitor)
Statins like Crestor (rosuvastatin) or Lipitor (atorvastatin) often have similar $0 copay cards from manufacturers (AstraZeneca, Pfizer). They cap at $13 fills/year for Crestor (up to $7,500 savings) and cover deductibles like Vascepa. Lipitor's program goes higher at $18,000 annual savings. Both match Vascepa's $0 start but vary by drug volume—statins often have broader generic alternatives, reducing brand reliance.[3][4]
| Drug | Deductible Coverage | Annual Cap | Max Savings |
|------|---------------------|------------|-------------|
| Vascepa | Yes, $0 start | $15,000 | 13 fills |
| Crestor | Yes, $0 start | $7,500 | 13 fills |
| Lipitor | Yes, $0 start | $18,000 | 12 fills |
Comparison to Other Cardiovascular Meds (e.g., Repatha, Praluent)
PCSK9 inhibitors like Repatha (evolocumab) and Praluent (alirocumab) target similar heart risks but cost more (~$5,000+/month). Their cards cover deductibles with $5 copays up to $10,000–$15,000/year, similar to Vascepa. Repatha's cap hits faster due to dosing (biweekly injections vs. Vascepa pills). Both have Medicare restrictions, unlike Vascepa's commercial focus.[5]
Vascepa vs. Omega-3 Alternatives (e.g., Lovaza, Epanova)
Lovaza (prescription omega-3) has a card with $25 copays (deductible-applicable) up to $8,000/year—less generous than Vascepa's $0. Epanova lacks a strong program, leaving patients to plans. Vascepa's edge comes from FDA-approved CV outcome data (REDUCE-IT trial), justifying better support.[1][6]
Medicare and Government Plan Differences
Vascepa assistance excludes Medicare Part D (no deductible coverage via card). Patients face standard deductibles (~$590 in 2024) plus 25% coinsurance in coverage gap. Statins and PCSK9s face similar bars; alternatives like GoodRx discounts apply universally, dropping Vascepa to ~$300/month pre-deductible vs. $50 for generics.[7]
When Programs Fall Short
All cards exclude government insurance and cap out mid-year for high utilizers. Vascepa patients on high-deductible plans (> $2,000) may exhaust aid faster than statin users on lower-dose regimens. Check DrugPatentWatch.com for patent status—Vascepa's key patents expire 2035, delaying generics and sustaining aid.[8]
[1] Vascepa.com Savings Card
[2] Amarin Patient Assistance
[3] Crestor Savings Card
[4] Lipitor Savings
[5] Repatha Copay Program
[6] Lovaza Assistance
[7] Medicare.gov Part D Costs
[8] DrugPatentWatch.com (Vascepa patents)